RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)

RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

RNA interference mediated inhibition of Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucelic acid (siNA)

RNA interference mediated inhibition of MYC and/or MYB gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)

Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics

Metabolic profile directed aptamer medicinal chemistry

Stabilized immune modulatory RNA (SIMRA) compounds

Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics

MicroRNA and methods for inhibiting same

RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics

Synthetic agonists of TLR9

High viscosity macromolecular compositions for treating ocular conditions

Aptamer-mediated intracellular delivery of oligonucleotides

Platelet derived growth factor (PDGF) nucleic acid ligand complexes

RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)

Polycationic compositions for cellular delivery of polynucleotides

RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

Kits and methods for generating 5' capped RNA

Compounds and Methods for Rna Interference of the P65 Subunit of Nf-Kappa-B

Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)

Dbait and uses thereof

Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)

Oligonucleotide analogues incorporating 5-aza-cytosine therein

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

Aptamer medicinal chemistry

Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics

RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA

Aptamer therapeutics useful in the treatment of complement-related disorders

Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)

Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)

Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies

Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor

Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation

Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Methods and compositions for treating ocular disorders

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference compositions and methods

Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics

Oligomeric compounds and compositions for use in modulation of pri-mirnas

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)

RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)

Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Delivery of polynucleotide agents to the central nervous system

Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics

Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics

Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof

Method for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels

Enzymatic nucleic acid treatment of diseases or conditions related to levels of IKK-gamma and PKR

Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides

RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

RNA interference mediated inhibition of MAP kinase gene expression or expression of genes involved in MAP kinase pathway using short interfering nucleic acid (siNA)

Effective and stable DNA enzymes

Aptamer therapeutics useful in the treatment of complement-related disorders

Aptamer-mediated intracellular delivery of therapeutic oligonucleotides

Tenascin-C nucleic acid ligands

Methods and materials for treating human papillomavirus infections

Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics

RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

Aptamer therapeutics useful in the treatment of complement-related disorders

RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)

RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering RNA

RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)

Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

MicroRNA and methods for inhibiting same

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Vascular therapeutics

Polycationic compositions for cellular delivery of polynucleotides

Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity

RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)

Three component chimeric antisense oligonucleotides

RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)

RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)

RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)

Chemically modified double stranded nucleic acid molecules

RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Antisense oligonucleotides against tenascin for the treating of vitiligo

RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)

RNA interference mediated target discovery and target validation using short interfering nucleic acid (siNA)

RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)

Vascular therapeutics

RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)

RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)

Tissue-specific and pathogen-specific ribozymes

RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)

5'-and 3'-capped aptamers and uses therefor

RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

Use of double-stranded ribonucleic acid for inducing cell lysis

Platelet derived growth factor (PDGF) nucleic acid ligand complexes

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

Methods for identifying aptamer regulators